27 research outputs found
Recommended from our members
Structural characterization of the PEAK3/14-3-3 and PI3Kα/KRas complexes
Cell communication is a dynamic process in which extracellular signals are transformed into biological responses through an intricate network of protein-protein interactions. These interactions can modulate cell signaling in a context-dependent manner, ensuring cellular homeostasis. Disruptions within these networks compromise normal cell communication, leading to disease. While the functional roles of many protein interaction partners have been studied in depth, their high-resolution structural characterization is lacking. Determining the structures of these integral protein complexes is essential to gain mechanistic insight into their functions and to understand how these very mechanisms are perturbed in disease. Here, we present the structural characterization of two protein complexes which are important regulators of cell signaling: PEAK3/14-3-3 and PI3Kα/KRas. We reveal that the dimeric PEAK3 scaffold associates with 14-3-3 in a unique asymmetric binding mode stabilized by a canonical phosphosite-dependent primary interface and an unusual secondary interface not seen in previous 14-3-3/client complexes. The secondary interface, which is largely stabilized by the SHED domain of PEAK3, explains why PEAK3 dimerization is essential for its scaffolding function. Additionally, we show that 14-3-3 sequesters PEAK3 in the cytosol, where it further modulates PEAK3’s interactome. We also elucidate membrane-bound structures of the lipid kinase PI3Kα in complex with KRas, revealing dynamic changes in PI3Kα during activation. Our structures demonstrate that when bound to POPC/POPS membranes, PI3Kα adopts three distinct conformations which model various stages of its activation trajectory. When bound to PIP2-containing membranes, the orientation of PI3Kα relative to the membrane changes significantly, tightly aligning its active site with the membrane and inducing conformational changes in key regulatory motifs. Most remarkably, the addition of an activating phosphopeptide induces dimerization of the PI3Kα/KRas complex, which is facilitated by an interface that is sterically occluded in auto-inhibited PI3Kα. Together, our studies provide the first structural characterization of the PEAK3/14-3-3 and PI3Kα/KRas complexes, offering mechanistic insights into their roles as regulators of cell migration and survival, respectively
Recommended from our members
Protein Stability Effects in Aggregate-Based Enzyme Inhibition
Small-molecule aggregates are a leading cause of artifacts in early drug discovery, but little is known about their interactions with proteins, nor why some proteins are more susceptible to inhibition than others. A possible reason for this apparent selectivity is that aggregation-based inhibition, as a stoichiometric process, is sensitive to protein concentration, which varies across assays. Alternatively, local protein unfolding by aggregates may lead to selectivity since stability varies among proteins. To deconvolute these effects, we used differentially stable point mutants of a single protein, TEM-1 β-lactamase. Broadly, destabilized mutants had higher affinities for and were more potently inhibited by aggregates versus more stable variants. The addition of the irreversible inhibitor moxalactam destabilized several mutants, and these typically bound tighter to a colloidal particle, while the only mutant it stabilized bound weaker. These results suggest that less-stable enzymes are more easily sequestered and inhibited by colloidal aggregates
Recommended from our members
Triggered Release Enhances the Cytotoxicity of Stable Colloidal Drug Aggregates
Chemotherapeutics that self-assemble into colloids have limited efficacy above their critical aggregation concentration due to their inability to penetrate intact plasma membranes. Even when colloid uptake is promoted, issues with colloid escape from the endolysosomal pathway persist. By stabilizing acid-responsive lapatinib colloids through coaggregation with fulvestrant, and inclusion of transferrin, we demonstrate colloid internalization by cancer cells, where subsequent lapatinib ionization leads to endosomal leakage and increased cytotoxicity. These results demonstrate a strategy for triggered drug release from stable colloidal aggregates
Recommended from our members
Identification of Novel Smoothened Ligands Using Structure-Based Docking.
The seven transmembrane protein Smoothened is required for Hedgehog signaling during embryonic development and adult tissue homeostasis. Inappropriate activation of the Hedgehog signalling pathway leads to cancers such as basal cell carcinoma and medulloblastoma, and Smoothened inhibitors are now available clinically to treat these diseases. However, resistance to these inhibitors rapidly develops thereby limiting their efficacy. The determination of Smoothened crystal structures enables structure-based discovery of new ligands with new chemotypes that will be critical to combat resistance. In this study, we docked 3.2 million available, lead-like molecules against Smoothened, looking for those with high physical complementarity to its structure; this represents the first such campaign against the class Frizzled G-protein coupled receptor family. Twenty-one high-ranking compounds were selected for experimental testing, and four, representing three different chemotypes, were identified to antagonize Smoothened with IC50 values better than 50 μM. A screen for analogs revealed another six molecules, with IC50 values in the low micromolar range. Importantly, one of the most active of the new antagonists continued to be efficacious at the D473H mutant of Smoothened, which confers clinical resistance to the antagonist vismodegib in cancer treatment
Structural insights into regulation of the PEAK3 pseudokinase scaffold by 14-3-3
Abstract PEAK pseudokinases are molecular scaffolds which dimerize to regulate cell migration, morphology, and proliferation, as well as cancer progression. The mechanistic role dimerization plays in PEAK scaffolding remains unclear, as there are no structures of PEAKs in complex with their interactors. Here, we report the cryo-EM structure of dimeric PEAK3 in complex with an endogenous 14-3-3 heterodimer. Our structure reveals an asymmetric binding mode between PEAK3 and 14-3-3 stabilized by one pseudokinase domain and the SHED domain of the PEAK3 dimer. The binding interface contains a canonical phosphosite-dependent primary interaction and a unique secondary interaction not observed in previous structures of 14-3-3/client complexes. Additionally, we show that PKD regulates PEAK3/14-3-3 binding, which when prevented leads to PEAK3 nuclear enrichment and distinct protein-protein interactions. Altogether, our data demonstrate that PEAK3 dimerization forms an unusual secondary interface for 14-3-3 binding, facilitating 14-3-3 regulation of PEAK3 localization and interactome diversity
An Aggregation Advisor for Ligand Discovery
Colloidal aggregation of organic molecules is the dominant mechanism for artifactual inhibition of proteins, and controls against it are widely deployed. Notwithstanding an increasingly detailed understanding of this phenomenon, a method to reliably predict aggregation has remained elusive. Correspondingly, active molecules that act via aggregation continue to be found in early discovery campaigns and remain common in the literature. Over the past decade, over 12 thousand aggregating organic molecules have been identified, potentially enabling a precedent-based approach to match known aggregators with new molecules that may be expected to aggregate and lead to artifacts. We investigate an approach that uses lipophilicity, affinity, and similarity to known aggregators to advise on the likelihood that a candidate compound is an aggregator. In prospective experimental testing, five of seven new molecules with Tanimoto coefficients (Tc’s) between 0.95 and 0.99 to known aggregators aggregated at relevant concentrations. Ten of 19 with Tc’s between 0.94 and 0.90 and three of seven with Tc’s between 0.89 and 0.85 also aggregated. Another three of the predicted compounds aggregated at higher concentrations. This method finds that 61 827 or 5.1% of the ligands acting in the 0.1 to 10 µM range in the medicinal chemistry literature are at least 85% similar to a known aggregator with these physical properties and may aggregate at relevant concentrations. Intriguingly, only 0.73% of all drug-like commercially available compounds resemble the known aggregators, suggesting that colloidal aggregators are enriched in the literature. As a percentage of the literature, aggregator-like compounds have increased 9-fold since 1995, partly reflecting the advent of high-throughput and virtual screens against molecular targets. Emerging from this study is an aggregator advisor database and tool (http://advisor.bkslab.org), free to the community, that may help distinguish between fruitful and artifactual screening hits acting by this mechanism
Recommended from our members
Structural insights into regulation of the PEAK3 pseudokinase scaffold by 14-3-3.
PEAK pseudokinases are molecular scaffolds which dimerize to regulate cell migration, morphology, and proliferation, as well as cancer progression. The mechanistic role dimerization plays in PEAK scaffolding remains unclear, as there are no structures of PEAKs in complex with their interactors. Here, we report the cryo-EM structure of dimeric PEAK3 in complex with an endogenous 14-3-3 heterodimer. Our structure reveals an asymmetric binding mode between PEAK3 and 14-3-3 stabilized by one pseudokinase domain and the SHED domain of the PEAK3 dimer. The binding interface contains a canonical phosphosite-dependent primary interaction and a unique secondary interaction not observed in previous structures of 14-3-3/client complexes. Additionally, we show that PKD regulates PEAK3/14-3-3 binding, which when prevented leads to PEAK3 nuclear enrichment and distinct protein-protein interactions. Altogether, our data demonstrate that PEAK3 dimerization forms an unusual secondary interface for 14-3-3 binding, facilitating 14-3-3 regulation of PEAK3 localization and interactome diversity
Stable Colloidal Drug Aggregates Catch and Release Active Enzymes
Small
molecule aggregates are considered nuisance compounds in
drug discovery, but their unusual properties as colloids could be
exploited to form stable vehicles to preserve protein activity. We
investigated the coaggregation of seven molecules chosen because they
had been previously intensely studied as colloidal aggregators, coformulating
them with bis-azo dyes. The coformulation reduced colloid sizes to
<100 nm and improved uniformity of the particle size distribution.
The new colloid formulations are more stable than previous aggregator
particles. Specifically, coaggregation of Congo Red with sorafenib,
tetraiodophenolphthalein (TIPT), or vemurafenib produced particles
that are stable in solutions of high ionic strength and high protein
concentrations. Like traditional, single compound colloidal aggregates,
the stabilized colloids adsorbed and inhibited enzymes like β-lactamase,
malate dehydrogenase, and trypsin. Unlike traditional aggregates,
the coformulated colloid-protein particles could be centrifuged and
resuspended multiple times, and from resuspended particles, active
trypsin could be released up to 72 h after adsorption. Unexpectedly,
the stable colloidal formulations can sequester, stabilize, and isolate
enzymes by spin-down, resuspension, and release